

**Supplementary Table 1.** Baseline characteristics of the studies

Study	Year	Country	Location of malignant colon obstruction	Study design	Age (yr) <sup>(a),(b)</sup>	Male/female	Tumor location	Pathological staging
Alhassan et al. <sup>15</sup>	2023	Saudi Arabia	Left-sided	Retrospective cohort	59.5 <sup>(a)</sup>	11/6	Splenic flexure 1/17, descending colon 3/17, sigmoid 13/17	TNM I, 0/17; TNM II, 5/17; TNM III, 12/17
Alcántara et al. <sup>25</sup>	2011	Spain	Left-sided	Prospective RCT	71.9 <sup>(a)</sup>	5/10	Splenic flexure 2/15, descending colon 1/15, sigmoid 11/15, rectosigmoid 0/15, rectum 1/3 sup 1/15	TNM I, 0/15; TNM II, 2/15; TNM III, 11/15; TNM IV, 2/15
Alkhalay et al. <sup>5</sup>	2020	Saudi Arabia	Both/unspecified	Retrospective cohort	59.5 <sup>(a)</sup>	14/10	Right 1/24, transverse 2/24, left 6/24, sigmoid 4/24, rectosigmoid 11/24	TNM I, 0/24; TNM II, 9/24; TNM III, 9/24; TNM IV, 6/24
Arnarson et al. <sup>1</sup>	2023	Sweden	Both/unspecified	Retrospective cohort	70	84/59	Right 8/143, transverse 8/143, left 127/143	T1-T3, 92/143; T4, 45/143; TX, 6/143; N0, 61/143; N1-2, 75/143; NX 6/143, M0, 115/143; M1, 27/143
Amelung et al. <sup>4</sup>	2019	The Netherlands	Left-sided	Retrospective study	72	124/98	Splenic flexure 15/222, descending colon 45/222, sigmoid 162/222	T1-T2, 11/222; T3, 158/222; T4, 51/222; N0, 105/222; N1, 73/222; N2, 41/222; M0, 200/222; M1, 22/222
Angenete et al. <sup>19</sup>	2012	Sweden	Both/unspecified	Prospective non-RCT study	73	57/55	Colon 92/112, rectal 20/112	-
Arezzo et al. <sup>17</sup>	2020	Italy	Both/unspecified	RCT	72 <sup>(a)</sup>	28/28	Splenic flexure 5/56, descending colon 43/56, sigmoid 8/56	T2, 2/56; T3, 37/56; T4, 15/56; N0, 27/56; N1, 19/56; N2, 8/56; M0, 52/56; M1, 4/56
Browne et al. <sup>20</sup>	2022	Canada	Both/unspecified	Retrospective study	63 <sup>(a)</sup>	34/24	Splenic flexure 5/58, descending colon 11/58, sigmoid 33/58, rectosigmoid 1/58, rectum 5/58, transverse colon 1/58, unspecified 2/58	T2, 2/58; T3, 37/58; T4, 19/58
Cao et al. <sup>18</sup>	2021	China	Left sided	Retrospective observational study	68 <sup>(a)</sup>	36/13	Splenic flexure 8/49, descending colon 6/49, sigmoid 35/49	T1, 1/49; T2, 1/49; T3, 19/49; T4, 28/49; N0, 25/49; N1, 19/49; N2, 5/49; M0, 41/49; M1, 8/49
Cheung et al. <sup>21</sup>	2009	China	Left sided	RCT	64.5	14/10	-	TNM I, 1/24; TNM II, 7/24; TNM III, 13/24; TNM IV, 3/24
Choi et al. <sup>22</sup>	2014	Korea	Both/unspecified	Retrospective study	65.2 <sup>(a)</sup>	45/15	Cecum 0/60, Ascending colon 2/60, Hepatic flexure 1/60, transverse colon 2/60, descending colon 6/60, Recto-sigmoid colon 49/60	-
Dolan et al. <sup>2</sup>	2021	United States	Both/unspecified	Retrospective study	63	84/55	Sigmoid/rectum 72/139, all colon 67/139	-
Fiori et al. <sup>23</sup>	2012	Italy	Left sided	Prospective RCT study	77.2 <sup>(a)</sup>	6/5	Sigmoid 4/11, rectal 7/11	T4, 11/11
Flor-Lorente et al. <sup>24</sup>	2017	Spain	Left sided	Prospective non-RCT study	72	15/12	Splenic flexure 6/27, descending 3/27, sigmoid 15/27, rectosigmoid 3/27	TNM I, 1/27; TNM II, 13/27; TNM III, 10/27; TNM IV, 3/27

(Continued to the next page)

Study	Year	Country	Location of malignant colon obstruction	Study design	Age (yr) <sup>(a),(b)</sup>	Male/female	Tumor location	Pathological staging
Paniagua García-Señoráns et al. <sup>16</sup>	2023	Spain	Both/unspecified	Retrospective cohort study	71.2 <sup>(a)</sup>	63/51	Right side 9/114, left side 100/114, rectum 5/114	TNM I, 4/114; TNM II, 48/114; TNM III, 62/114
Ghazal et al. <sup>26</sup>	2013	Egypt	Left sided	Prospective RCT study	52	12/18	Rectosigmoid 12/30, sigmoid 14/30, descending 4/30	TNM I, 6/30; TNM II, 19/30; TNM III, 5/30
Gianotti et al. <sup>27</sup>	2013	Italy	Both/unspecified	Prospective cohort	69 <sup>(b)</sup>	42/7	Right colon 0/49, transverse colon 3/49, left colon 20/49, rectosigmoid 26/49	T2, 16/49; T3, 17/49; T4, 12/49
Gorissen et al. <sup>28</sup>	2013	UK	Left sided	Prospective cohort	70.6 <sup>(a)</sup>	36/26	Splenic flexure 12/62, descending colon 14/62, sigmoid 36/62	T2, 0/62; T3, 33/62; T4, 29/62
Harvey et al. <sup>29</sup>	2019	UK	Both/unspecified	Retrospective study	71 <sup>(b)</sup>	212/163	-	-
Han et al. <sup>30</sup>	2020	China	Left sided	Retrospective study	60.3	50/34	Descending colon 32/84, sigmoid colon 40/84, rectum 12/84	TNM II, 12/84; TNM III, 57/84; TNM IV, 15/84
Hidalgo-Pujol et al. <sup>3</sup>	2022	Spain	Left sided	Retrospective study	75.1 <sup>(b)</sup>	152/92	Transverse colon 4/244, splenic flexure 31/244, descending colon 45/244, sigmoid colon 136/244, recto-sigma 28/244	TNM I, 8/244; TNM II, 120/244; TNM III, 116/244
Ho et al. <sup>31</sup>	2012	Singapore	Left sided	RCT	68 <sup>(b)</sup>	13/7	Rectosigmoid colon 5/20, sigmoid colon 10/20, descending colon 3/20, splenic flexure 2/20	T2, 7/20; T3, 10/20; T4, 3/20
van Hooft et al. <sup>32</sup>	2011	The Netherlands	Left sided	RCT	70.4 <sup>(a)</sup>	24/23	-	-
Kang et al. <sup>34</sup>	2018	Korea	Left sided	Retrospective cohort study	64.4 <sup>(a)</sup>	141/85	Splenic flexure 9/226, descending colon 23/226, sigmoid colon 161/226, upper rectum 33/226	T2, 97/226; T3, 129/226
Katsuki et al. <sup>35</sup>	2021	Japan	Left sided	Retrospective cohort study	73 <sup>(b)</sup>	272/226	Splenic flexure 9/498, descending colon 145/498, sigmoid colon 344/498	TNM I-II, 34/498; TNM III, 307/498; TNM IV, 157/498
Khomvilai et al. <sup>36</sup>	2023	Thailand	Left sided	Retrospective cohort study	68 <sup>(a)</sup>	32/17	Splenic flexure 0/49, descending colon 8/49, sigmoid colon 21/49, rectosigmoid colon 20/49	TNM I, 0/49; TNM II, 12/49; TNM III, 21/49; TNM IV, 16/49
Kim et al. <sup>37</sup>	2013	Korea	Left sided	Retrospective study	61.6 <sup>(a)</sup>	15/10	Splenic flexure 1/25, descending colon 0/25, sigmoid colon 17/25, rectum 7/25	TNM I, 0/25; TNM II, 11/25; TNM III, 9/25; TNM IV, 5/25
Kim et al. <sup>6</sup>	2023	Korea	Both	Retrospective study	65.2 <sup>(a)</sup>	46/69	Right colon 17/115, left colon 98/115	TNM II, 44/115; TNM III, 63/115; TNM IV, 8/115
Li et al. <sup>38</sup>	2020	China	Right sided	Retrospective study	66 <sup>(b)</sup>	21/14	Cecum 0 (0%), ascending colon 12 (34.3%), hepatic flexure 7 (20%), transverse colon 16 (45.7%)	TNM II, 16 (45.7%); TNM III, 12 (34.3%); TNM IV, 7 (20%)

(Continued to the next page)

Study	Year	Country	Location of malignant colon obstruction	Study design	Age (yr) <sup>(a),(b)</sup>	Male/female	Tumor location	Pathological staging
Mahfouz et al. <sup>39</sup>	2022	Egypt	left sided	Observational nonrandomized study	69 <sup>(a)</sup>	26/35, 9/35	Sigmoid 34 (97.1%), rectum 1 (2.9%)	-
Merabishvili et al. <sup>40</sup>	2021	Georgia	left sided	Prospective Study	61.8 <sup>(a)</sup>	9/14, 5/14	Splenic flexure 1 (7.1%), descending colon 1 (7.1%), sigmoid colon 8 (57.1%), rectosigmoid colon 4 (28.6%)	T2, 4 (28.6%); T3, 9 (64.3%); T4, 1 (7.1%)
Crespi-Mir et al. <sup>63</sup>	2018	Spain	Both/unspecified	Retrospective study	68.7 <sup>(a)</sup>	38/57, 19/57	Right colon 7 (12.3%), left colon, rectum 50 (87.7%)	T1, 23 (40.4%); T2, 30 (52.6%); T3, 2 (3.5%); T4, 2 (3.5%)
Morita et al. <sup>41</sup>	2019	Japan	Left sided	Retrospective study	70 <sup>(a)</sup>	41/40	Descending 22/81, sigmoid 34/81, rectosigmoid 15/81, upper rectum 9/81, lower rectum 1/81	TNM I, 0/81; TNM II, 29/81; TNM III, 27/81; TNM IV, 25/81
Morita et al. <sup>41</sup>	2019	Japan	Right sided	Retrospective study	74 <sup>(a)</sup>	10/18	Cecum 0/28, ascending 11/28, transverse 17/28	TNM I, 1/28; TNM II, 6/28; TNM III, 10/28; TNM IV, 11/28
Mu et al. <sup>42</sup>	2023	China	Left sided	Retrospective study	68.69 <sup>(a)</sup>	10/3	Splenic flexure 0 (0%), descending colon 8 (61.5%), sigmoid 3 (23.1%), rectosigmoid 2 (15.4%)	TNM II, 4 (30.8%); TNM III, 5 (38.5%); TNM IV, 4 (30.8%)
Park et al. <sup>43</sup>	2018	Korea	Left sided	Retrospective study	64 <sup>(a)</sup>	52/94, 42/94	Descending colon 13 (13.8%), sigmoid colon 59 (62.8%), rectum 22 (23.4%)	T1, 0 (0%); T2, 0 (0%); T3, 69 (73.4%); T4, 25 (26.8%); N0, 5 (5.3%); N1, 51 (54.3%); N2, 38 (40.4%)
Rodrigues-Pinto et al. <sup>44</sup>	2019	Portugal	Left sided	Retrospective study	67 <sup>(b)</sup>	25/48, 23/48	Rectum 7 (14.6%), sigmoid 30 (62.5%), descending colon 11 (22.9%)	TNM I, 0 (0%); TNM IIa, 11 (22.9%); TNM IIb, 3 (6.2%); TNM IIIa, 1 (2.1%); TNM IIb, 18 (37.5%); TNM IIIc, 2 (4.2%); TNM IVa, 9 (18.8%); TNM IVb, 4 (8.3%)
Pirlet et al. <sup>45</sup>	2011	France	left sided	Prospective study	70.4 <sup>(a)</sup>	16/30, 14/30	Rectosigmoid 8 (26.7%), sigmoid colon 15 (50%), descending colon 6 (20%), splenic flexure 0 (0%)	-
Ptok et al. <sup>46</sup>	2006	Germany	Both/unspecified	Prospective study	79 <sup>(b)</sup>	19/38, 19/38	Ascending colon 1 (2.6%), right flexure 1 (2.6%), transverse colon 3 (7.9%), left flexure 1 (2.6%), descending colon 2 (5.3%), sigmoid colon 17 (44.7%), rectum 13 (44.2%)	-
Lara-Romero et al. <sup>47</sup>	2019	Spain	Left sided	Retrospective study	69 <sup>(b)</sup>	43/71, 28/71	Left colon 23 (32.4%), sigmoid colon 32 (45.1%), rectosigmoid union 4 (5.6%), upper rectum 12 (16.9%)	T1-2, 8 (11.3%); T3, 45 (63.4%); T4, 18 (25.4%); N0, 40 (56.3%); N1, 19 (26.8%); N2, 12 (16.9%)

(Continued to the next page)

**Supplementary Table 1.** Continued

Study	Year	Country	Location of malignant colon obstruction	Study design	Age (yr) <sup>(a),(b)</sup>	Male/female	Tumor location	Pathological staging
Scomparin et al. <sup>48</sup>	2020	Brazil	Left sided	Retrospective study	59.1 <sup>a)</sup>	9/21, 12/21	Descending colon 5 (23.8%), sigmoid colon 6 (28.5%), rectum 10 (47.6%)	T2, 3 (14.2%); T3, 11 (52.3%); T4, 7 (33.3%); N0, 10 (47.6%); N1, 5 (23.8%); N2, 6 (28.6%); M0, 18 (85.7%); M1, 3 (14.3%) TNM I, 0 (0%); TNM II, 10 (38.5%); TNM III, 15 (57.7%); TNM IV, 1 (3.8%)
Sloothaak et al. <sup>49</sup>	2014	The Netherlands	Both/unspecified	Retrospective study	67 <sup>b)</sup>	12/14		
Tanis et al. <sup>50</sup>	2015	The Netherlands	Left sided	Prospective study	71 <sup>b)</sup>	119/196, 77/196	Sigmoid 144 (73.5%), descending colon 34 (17.3%), splenic flexure 18 (9.2%)	T1, 1 (0.5%); T2, 12 (6.3%); T3, 141 (73.8%); T4, 37 (19.4%); N0, 95 (49.2%); N1-2, 96 (49.8%); Nx, 2 (1%); M0, 124 (66%); M1, 45 (23.9%); unknown 19 (10.1%)
Bin Traiki et al. <sup>51</sup>	2023	Saudi Arabia	Both/unspecified	Retrospective study	56.9 <sup>a)</sup>	90/145, 55/145	Rectosigmoid junction 26 (17.9%), sigmoid colon 50 (34.5%), descending colon 24 (16.6%), transverse colon 11 (7.6%), ascending colon 22 (15.2%), cecum 2 (15.2%)	TNMI, 31 (21.4%); TNM II, 41 (28.3%); TNM III, 56 (38.6%); TNM IV, 17 (11.7%)
Tung et al. <sup>52</sup>	2013	Hong Kong	Left sided	Prospective study	64.5 <sup>b)</sup>	14/24, 10/24	-	TNM I, 1 (4.2%); TNM II, 7 (29.2%); TNM III, 14 (58.3%); TNM IV, 2 (8.3%)
Uehara et al. <sup>53</sup>	2022	Japan	Both/unspecified	Retrospective study	69 <sup>b)</sup>	24/43, 19/43	Right-sided 12 (27.9%), left-sided 31 (72.1%)	TNM II-III, 27 (62.8%); TNM IV 16 (37.2%)
van Hooft et al. <sup>53</sup>	2007	The Netherlands	Left sided	Prospective study	61.5 <sup>a)</sup>	4/11, 7/11	Rectosigmoid 7 (64%), descending colon 4 (36%)	TNM IV 11 (100%)
Wang et al. <sup>55</sup>	2019	China	Both/unspecified	Retrospective study	66.1 <sup>a)</sup>	21/37, 16/37	Right-sided 11 (29.7%), left-sided 26 (70.3%)	TNM II, 14 (37.9%); TNM III, 16 (43.2%); TNM IV, 7 (18.9%)
Wang et al. <sup>54</sup>	2020	China	Both/unspecified	Retrospective study	64.3 <sup>a)</sup>	25/45, 20/45	Right-sided 25 (55.6%), left-sided 20 (44.4%)	TNM II, 17 (37.8%); TNM III, 23 (51.1%); TNM IV, 5 (11.1%)
Xue et al. <sup>56</sup>	2020	China	Both/unspecified	Retrospective study	73 <sup>b)</sup>	25/33, 8/33	Ascending colon 4 (12.1%), transverse colon 2 (6.1%), descending colon 10 (30.3%), sigmoid colon 17 (51.5%)	TNM I, 2 (6.1%); TNM II, 15 (45.4%); TNM III, 13 (39.4%); TNM IV, 3 (9.1%)
Yagawa et al. <sup>57</sup>	2021	Japan	Both/unspecified	Retrospective study	66 <sup>b)</sup>	14/25, 11/25	Cecum 0, ascending colon 2 (8%), transverse colon 6 (24%), descending colon 3 (12%), sigmoid colon 12 (48%), rectum 2 (8%)	TNM II, 6 (24%); TNM III, 15 (60%); TNM IV, 4 (16%)
Yan et al. <sup>58</sup>	2017	China	Both/unspecified	Retrospective study	60.4 <sup>a)</sup>	21 (77.8%)/6 (23.2%)	Cecum 0, ascending colon 1 (3.7%), hepatic flexure 1 (3.7%), transverse colon 0, descending colon 6 (22.2%), rectosigmoid colon 19 (70.4%)	TNM IIA, 8 (29.6%); TNM IIIA, 3 (11.1%); TNM IIIB, 3 (11.1%); TNM IIIC, 4 (14.8%); TNM IV, 9 (33.3%)

(Continued to the next page)

Study	Year	Country	Location of malignant colon obstruction	Study design	Age (yr) <sup>a),(b)</sup>	Male/female	Tumor location	Pathological staging
Zeng et al. <sup>59</sup>	2021	China	Right sided	Retrospective study	65.5 <sup>b)</sup>	57/98 41/98	Cecum 10 (10.2%), ascending colon 32 (32.7%), hepatic flexure 42 (42.9%), transverse colon 14 (14.3%)	TNM II, 38 (38.8%); TNM III, 60 (61.2%)
Martinez-Santos et al. <sup>60</sup>	2002	Spain	Left sided	Prospective study	71 <sup>a)</sup>	26/43 17/43	Rectum 14 (32.6%), sigmoid 18 (41.8%), left Colon 11 (25.6%)	Unspecified
van den Berg et al. <sup>62</sup>	2014	The Netherlands	Both	Retrospective study	71 <sup>a)</sup>	31/59, 28/59	Left sided 43 (72.9%), right sided 16 (27.1%)	TNM I, 3 (5.1%); TNM II, 24 (40.7%); TNM III, 20 (33.9%); TNM IV, 11 (18.6%)
Ji et al. <sup>61</sup>	2017	Korea	Right-sided	Retrospective study	61.5 <sup>a)</sup>	4/14, 10/14	Cecum 1 (7.1%), ascending colon 6 (42.9%), hepatic flexure 7 (50%)	TNM II, 4 (28.6%); TNM III, 5 (35.7%); TNM IV, 5 (35.7%)

RCT, randomized control trial -, data not available.

<sup>a)</sup>Mean, <sup>b)</sup>median.